In the last trading session, 1.07 million Bicara Therapeutics Inc (NASDAQ:BCAX) shares changed hands as the company’s beta touched 0. With the company’s per share price at $9.29 changed hands at $0.58 or 6.66% during last session, the market valuation stood at $506.64M. BCAX’s last price was a discount, traded about -202.37% off its 52-week high of $28.09. The share price had its 52-week low at $7.80, which suggests the last value was 16.04% up since then. When we look at Bicara Therapeutics Inc’s average trading volume, we note the 10-day average is 0.93 million shares, with the 3-month average coming to 876.44K.

Bicara Therapeutics Inc (NASDAQ:BCAX) trade information

Instantly BCAX was in green as seen at the end of in last trading. With action 1.20%, the performance over the past five days has been green. However, in the 30-day time frame, Bicara Therapeutics Inc (NASDAQ:BCAX) is -1.59% down. Looking at the short shares, we see there were 5.08 million shares sold at short interest cover period of 4.0 days.

The consensus price target for the stock as assigned by Wall Street analysts is 28, meaning bulls need an upside of 66.82% from its current market value. According to analyst projections, BCAX’s forecast low is 8 with 48 as the target high. To hit the forecast high, the stock’s price needs a -416.68% plunge from its current level, while the stock would need to tank 13.89% for it to hit the projected low.

The 2025 estimates are for Bicara Therapeutics Inc earnings to increase by 42.88%, but the outlook for the next 5-year period is at 11.95% per year.

BCAX Dividends

Bicara Therapeutics Inc is expected to release its next quarterly earnings report on 2025-May-13.

Bicara Therapeutics Inc (NASDAQ:BCAX)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 11.65% of Bicara Therapeutics Inc shares while 89.28% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 101.05%.